VE202

December 14, 2018December 14, 2018

Janssen Launching Phase 1 Trial Testing VE202 for Potential IBD Treatment

News

Janssen Biotech will conduct a Phase 1 clinical trial in healthy volunteers to test VE202, an investigational oral treatment for inflammatory bowel disease (IBD), Vedanta Biosciences has announced. In 2015, Janssen bought ... Read more

December 15, 2017

Vedanta Granted Four U.S. Patents for Therapeutics Based on Beneficial Gut Bacteria

News

Vedanta Biosciences has recently been granted four U.S. patents covering pharmaceutical compositions of therapeutics targeting inflammatory bowel disease (IBD) and other immune-mediated and infectious conditions. The new patents protect Vedanta’s therapeutic ... Read more

January 14, 2015January 14, 2015

Janssen Signs Licensing Agreement with Vedanta for IBD Treatment Development

IBD News, News

Philadelphia-based Janssen Biotech, Inc., a biotechnology company with a focus on developing diagnostic assays using monoclonal antibody technology, has just signed a strategic licensing agreement with Vedanta Biosciences, an expert in microbiology ... Read more